Company Overview
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical entity dedicated to developing therapeutic agents specifically for patients suffering from cancer. The company's product pipeline focuses on creating antibodies and small molecules designed to treat conditions including prostate cancer, lung cancer, breast cancer, and glioblastoma, alongside the development of KROS 101, an orally available agent. This entity functions within the healthcare sector, specifically classified under the biotechnology industry, which implies a high-risk, high-reward environment centered on research and development rather than mature manufacturing. The company's current market capitalization stands at $12.02M, while its annual revenue is not available for reporting, and it employs 1 individual. These valuation and operational scale figures indicate that Kairos Pharma is a micro-cap entity with minimal current revenue generation, reflecting its status as a pre-commercial or early-stage development company where value is derived primarily from intellectual property and future potential rather than current cash flows.
Financial Health
The company reports revenue of N/A for the trailing twelve months, a net income of $-5,062,000, and an EBITDA of $-5,443,000. The significant gap between revenue (which is unavailable) and the substantial net loss reveals a cost structure dominated by research and development expenditures typical of clinical-stage biopharmaceutical firms that have not yet achieved commercial product sales. Free cash flow stands at $-3,617,875, indicating that the company is burning cash to fund its operations and development efforts, which limits immediate financial flexibility but is a common characteristic of companies in the growth phase of their lifecycle. All three margins—gross margin, operating margin, and profit margin—are reported at 0.0%, a metric that indicates the company has not yet generated positive profitability from its sales activities. Total cash holdings amount to $5.58M, while debt is listed as N/A, and the debt-to-equity ratio is also N/A, suggesting the balance sheet is currently unleveraged and funded primarily through equity or cash reserves. The current ratio is 16.56, which indicates an exceptionally strong position regarding short-term liquidity, as the company possesses ample current assets to cover its current liabilities many times over. Return on Equity is -92.1% and Return on Assets is -53.6%, metrics that reveal management is currently destroying shareholder value and utilizing assets to generate negative returns, a standard pattern for early-stage biotechnology companies investing heavily in pipeline advancement before monetization.
Valuation Assessment
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is -1.76, a difference that implies the market is pricing in future earnings recovery but currently reflects the negative earnings trajectory in the forward metric. The price-to-book ratio is 1.57, which indicates that the market values the company's equity at a 57% premium over its book value, suggesting investors are willing to pay more for the company's assets based on its growth potential despite current losses. The price-to-sales ratio is N/A because revenue is not reported, and the EV/EBITDA is -1.19, suggesting that traditional earnings-based valuation multiples are not applicable due to the company's negative earnings and cash conversion status. The stock's 52-week high is $2.11 and the 52-week low is $0.40, placing the current trading price within this historical range and subject to significant intrayear volatility. The beta value is N/A, meaning that the company's price volatility relative to the broader market cannot be quantified with the provided data, though the wide spread between the 52-week high and low suggests inherent high volatility typical of small-cap biotechnology stocks.
Growth & Income
Revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue, though the lack of data confirms the company is in a stage where historical growth metrics are not yet established. The company does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, which means the company reinvests all available earnings and cash reserves back into research, development, and operational growth rather than distributing income to shareholders. This non-dividend profile is consistent with clinical-stage biopharmaceutical companies that prioritize capital allocation toward advancing their therapeutic pipeline for cancer treatments over providing immediate income returns. Consequently, the overall growth and income profile is characterized by a complete reliance on capital appreciation and future commercialization potential, with no current income generation or historical growth data available to assess the trajectory of the business.